RenovoRx announces positive interim Phase III data: RenovoGem delays progression by 8 months in pancreatic cancer

RenovoRx, Inc.

Interim Phase III data show RenovoGem delays cancer progression by 8 months in locally advanced pancreatic cancer.
RenovoRx issued press release on June 29, 2023 detailing positive interim results from ongoing trial.
RenovoGem is delivered via RenovoRx's proprietary targeted therapy platform for difficult-to-treat cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.